phone
word
count
abstract
word
count
text
highlight
immun
statu
significantli
differ
sever
nonsever
decreas
lymphocyt
correl
cours
patient
level
lymphocyt
indic
sever
prognosi
abstract
object
explor
clinic
cours
dynam
featur
immun
statu
patient
find
predictor
correl
sever
prognosi
method
electron
medic
record
patient
pneumonia
confirm
nucleic
acid
test
retrospect
collect
analyz
result
patient
divid
sever
nonsever
group
lymphocyt
subset
count
includ
cell
cell
cell
b
cell
nk
j
u
r
n
l
p
r
e
p
r
f
cell
significantli
lower
sever
group
dynam
level
lymphocyt
sever
group
significantli
lower
diseas
onset
improv
subgroup
valu
lymphocyt
began
increas
treatment
final
return
normal
level
cutoff
valu
count
cell
calcul
indic
significantli
high
sensit
specif
sever
conclus
result
shown
decreas
lymphocyt
correl
cours
patient
pneumonia
especi
sever
case
level
lymphocyt
could
use
indic
predict
sever
prognosi
patient
pneumonia
applic
glucocorticoid
cautiou
sever
case
ige
iuml
j
u
r
n
l
p
r
e
p
r
f
decemb
acut
viral
respiratori
diseas
name
coronaviru
diseas
report
wuhan
china
caus
novel
coronaviru
sever
acut
respiratori
syndrom
coronaviru
world
health
organ
list
novel
coronaviru
pneumonia
epidem
public
health
emerg
intern
concern
april
infect
confirm
world
clinic
present
vari
mild
sever
elder
patient
patient
known
comorbid
hypertens
diabet
cardiomyopathi
chronic
renal
failur
chronic
obstruct
pulmonari
diseas
copd
decreas
immun
appear
higher
risk
develop
sever
diseas
result
high
casefat
rate
retrospect
studi
show
mortal
sever
patient
earli
identif
intervent
underli
sever
patient
crucial
reduct
mortal
due
lack
specif
antivir
drug
vaccin
immun
statu
becom
one
crucial
factor
affect
diseas
progress
prognosi
clinic
laboratori
data
patient
reveal
case
display
signific
low
circul
lymphocyt
count
especi
sever
patient
admit
icu
aim
character
immun
statu
sever
nonsever
patient
pneumonia
review
correl
clinic
cours
dynam
chang
lymphocyt
subset
patient
attempt
find
indic
earli
identif
underli
sever
patient
pneumonia
retrospect
studi
patient
enrol
confirm
fluoresc
reversetranscriptasepolymeras
chain
reaction
frtpcr
assay
renmin
hospit
wuhan
univers
januari
februari
patient
divid
sever
nonsever
group
accord
pneumonia
diagnosi
treatment
program
novel
coronaviru
infect
trial
version
issu
nation
health
commiss
peopl
republ
china
http
wwwnhcgovcn
clinic
classif
summar
tabl
end
followup
februari
electron
medic
record
includ
epidemiolog
clinic
laboratori
radiolog
find
patient
collect
analyz
laboratori
result
obtain
within
earli
stage
diseas
case
incomplet
data
exclud
statist
analysi
perform
use
spss
softwar
graphpad
prism
softwar
percentag
frequenc
rate
use
describ
categor
variabl
mean
median
interquartil
rang
iqr
standard
deviat
sd
use
describ
continu
variabl
test
mannwhitney
test
use
compar
mean
continu
variabl
total
patient
enrol
studi
median
age
patient
iqr
patient
male
patient
comorbid
includ
hypertens
diabet
malign
chronic
lung
diseas
diseas
clinic
manifest
pneumonia
list
tabl
patient
divid
nonsever
sever
group
signific
differ
age
nonsever
iqr
sever
iqr
group
compar
nonsever
patient
comorbid
includ
hypertens
cardiovascular
diseas
cerebr
aneurysm
significantli
higher
sever
group
proport
patient
dyspnea
also
signific
higher
sever
group
chest
ct
import
method
diagnosi
pneumonia
signific
differ
nonsever
sever
group
bilater
multipl
lobe
lesion
seen
patient
signific
differ
laboratori
find
observ
nonsever
sever
group
tabl
patient
also
divid
age
age
group
signific
differ
count
lymphocyt
subset
two
group
fig
compar
patient
without
comorbid
count
lymphocyt
valu
humor
immun
igm
iga
signific
lower
patient
comorbid
fig
g
j
result
shown
level
lymphocyt
subset
normal
hospit
nonsever
group
fig
level
lymphocyt
signific
lower
patient
pneumonia
sever
group
fig
februari
patient
discharg
patient
hospit
patient
dead
result
indic
level
lymphocyt
subset
strongli
correl
cours
patient
roc
curv
area
roc
curv
auc
use
assess
diagnost
valu
identif
sever
result
shown
count
cell
significantli
high
sensit
specif
fig
f
pneumonia
simultan
cutoff
valu
calcul
accord
roc
curv
includ
cell
cell
cell
b
cell
nk
cell
sensit
specif
humor
immun
paramet
excel
auc
rang
lower
auc
lymphocyt
fig
g
addit
result
shown
cutoff
valu
lymphocyt
excel
identifi
sever
nonsever
group
patient
dynam
data
patient
sever
group
improv
transform
nonsever
type
treatment
cutoff
valu
lymphocyt
also
excel
predict
dynam
trend
diseas
j
u
r
n
l
p
r
e
p
r
f
high
infect
pathogen
basic
reproduct
number
estim
much
higher
sarscov
merscov
affin
receptor
time
higher
sarscov
without
therapeut
vaccin
specif
antivir
drug
earli
detect
intervent
underli
sever
patient
crucial
reduct
mortal
consist
previou
studi
averag
age
patient
comorbid
sever
group
significantli
higher
nonsever
group
distribut
gender
significantli
differ
two
group
sever
group
mortal
male
patient
higher
suggest
male
patient
may
tend
develop
sever
ill
epidemiolog
data
ccdc
also
indic
mortal
male
patient
higher
femal
sexbas
immunolog
differ
also
contribut
variat
suscept
infecti
diseas
respons
viru
signific
increas
white
blood
cell
neutrophil
decreas
lymphocyt
sever
patient
consist
studi
analysi
lymphocyt
subset
also
indic
count
lymphocyt
subset
significantli
declin
sever
patient
nonsever
group
biomark
matur
lymphocyt
help
activ
cell
cell
cell
cell
import
role
regul
maintain
stabil
intern
immun
environ
research
sar
shown
dramat
loss
patient
cell
patient
character
patient
acut
phase
sar
mechan
reduct
lymphocyt
may
associ
direct
invas
confirm
merscov
dendrit
cell
dc
cell
may
alter
function
apc
impair
dc
migrat
reduc
prime
lymphocyt
addit
affect
immun
cell
function
lymphocyt
also
regul
cytokin
proinflammatori
cytokin
promot
lymphocyt
apoptosi
interact
mainli
express
age
cell
immunolog
activ
cell
macrophag
b
lymphocyt
complement
system
critic
part
host
defens
mani
bacteri
viral
fungal
infect
complement
system
also
strictli
regul
number
inhibit
protein
serum
potenti
damag
host
tissu
result
shown
complement
significantli
higher
sever
patient
pneumonia
nonsever
patient
found
complement
activ
result
roc
curv
confirm
level
cell
perform
excel
sensit
specif
sever
cutoff
valu
lymphocyt
also
excel
predict
dynam
trend
diseas
facilit
detect
interven
underli
sever
patient
earlier
crucial
reduct
mortal
result
studi
also
provid
new
perspect
treatment
sever
glucocorticoid
suppress
cellmedi
immun
promot
decreas
lymphocyt
delay
viru
clearanc
may
aggrav
impair
function
lymphocyt
patient
therefor
use
glucocorticoid
cautiou
sever
patient
pneumonia
time
glucocorticoid
applic
deserv
explor
improv
lymphocyt
function
mayb
promis
therapi
sever
patient
pneumonia
studi
retrospect
analysi
approv
ethic
committe
renmin
hospit
wuhan
univers
approv
number
author
declar
conflict
interest
